You are here

seladelpar

FDA approves Gilead's seladelpar for primary biliary cholangitis

First Word Pharma

Wed, 08/14/24 - 10:35 pm

Gilead Sciences

primary biliary cholangitis

On doorstep of FDA decision, Gilead pays J&J $320M to exit licensing deal for seladelpar

Fierce Biotech

Fri, 08/9/24 - 11:23 am

Gilead Sciences

Gilead, Ipsen build the case for their PBC drugs at EASL

Pharmaphorum

Wed, 06/5/24 - 11:06 am

Gilead Sciences

primary biliary cholangitis

Gilead's new liver disease med continues to deliver the goods ahead of FDA verdict

Fierce Biotech

Mon, 05/20/24 - 10:59 am

Gilead Sciences

CymaBay Therapeutics

Gilead pays $4.3B for CymaBay, the biotech that never gave up on liver disease med

Fierce Biotech

Mon, 02/12/24 - 11:53 am

Gilead Sciences

CymaBay Therapeutics

primary biliary cholangitis

2 NASH drugmakers have wildly different Mondays

Biopharma Dive

Mon, 11/25/19 - 10:11 pm

Intercept Pharmaceuticals

CymaBay Therapeutics

obeticholic acid

CymaBay Therapeutics Stumbles in NASH Race, Shares Fall

Xconomy

Tue, 06/11/19 - 10:11 am

clinical trials

Upcoming events – a legal verdict for Enbrel and a clinical one for Cymabay

EP Vantage

Sat, 04/13/19 - 12:23 pm

CymaBay Therapeutics Reports Positive Results from Ph II Study of Seladelpar in Patients with Primary Biliary Cholangitis

CP Wire

Tue, 11/13/18 - 10:26 am

primary biliary cholangitis

CymaBay Therapeutics Reports Positive Results from Ph II Study of Seladelpar in Patients with Primary Biliary Cholangitis

Tue, 11/13/18 - 10:02 am

primary biliary cholangitis

CymaBay Initiates Ph III Study of Primary Biliary Cholangitis Drug

CP Wire

Tue, 10/30/18 - 11:22 am

primary biliary cholangitis

clinical trials

CymaBay Announces Positive Efficacy and Safety Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis

CP Wire

Wed, 04/11/18 - 11:57 pm

clinical trials